GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Other Operating Expense

HUTCHMED (China) (HUTCHMED (China)) Other Operating Expense : $0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Other Operating Expense?

HUTCHMED (China)'s Other Operating Expense for the six months ended in Dec. 2023 was $0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

HUTCHMED (China)'s quarterly Other Operating Expense increased from Dec. 2022 ($-0.0 Mil) to Jun. 2023 ($0.0 Mil) and increased from Jun. 2023 ($0.0 Mil) to Dec. 2023 ($0.0 Mil).

HUTCHMED (China)'s annual Other Operating Expense increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then stayed the same from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($0.0 Mil).


HUTCHMED (China) Other Operating Expense Historical Data

The historical data trend for HUTCHMED (China)'s Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Other Operating Expense Chart

HUTCHMED (China) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.25 - - - -

HUTCHMED (China) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HUTCHMED (China) Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China) Other Operating Expense Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


HUTCHMED (China) (HUTCHMED (China)) Business Description

Traded in Other Exchanges
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.